


Rotherham Place Prescribing

AUGUST 2025

 <https://mot.southyorkshire.icb.nhs.uk>

Bitesize

MO Team Mailbox Update

There is now a new email to contact Rotherham Medicines Optimisation Team. From 1 September 2025 this will be the only way to contact the SY MOT via email. Please update your contacts for future reference.

syicb-sheffield.syicb.medsopt1@nhs.net

In the interim all emails from the previous syicb-rotherham.medicinesmanagement@nhs.net will be diverted, but please start to use the new one from **1st September 2025**

Eclipse – Red Alerts

The safety incentive scheme for 24/25 includes an indicator for all the Eclipse RED high priority alerts to be reviewed.

It is important to note that the Eclipse system processes patients' data for alerts **weekly on a Sunday**, and records whether the practice review/address each patient from Monday to Saturday that following week.

Eclipse then provides the ICB with monthly reports showing the %age of alerts reviewed and **actioned within the week** they were found, and data for March 2026 will provide the results for achievement to be calculated.

Topiramate FAQs

Who can complete ARAF's for patients who are managed in primary care with migraines?

Any suitable qualified health care professional in the practice can complete the ARAF for the use of Topiramate in migraines, this includes GP, practice nurse or pharmacist.

What if patients don't want "highly effective contraception" but want to use combination of other methods? Should a TARAF be completed?

These patients will still need TARAF's completing and it should be stated pregnancy prevention has been declined as they are not on adequate contraception, therefore it is important these patients are reviewed for an alternative agent. These patients must also be audited if they remain on Topiramate as they are at high risk.

Reminder of codes to use:

- For **Referral** for completion of Topiramate Annual Risk Acknowledgement Form use: Pregnancy prevention programme (**Y20ab**)
- For **Completion** of Topiramate Annual Risk Acknowledgement Form use: Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form completed (**Ycj8Z**) and/or Topiramate Pregnancy Prevention Programme Annual Risks Form for Prophylaxis of Migraine (**Ycj8i**), Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for **Epilepsy** (**Ycj8j**)

Launch of NEW SY ICB Medicines Optimisation Website (1st Sept 2025)

From 1st September 2025, Medicines Optimisation (MO) documents will be available via our new website: <https://mot.southyorkshire.icb.nhs.uk>

This includes clinical and prescribing guidance, shared care protocols (SCP), community pharmacy documents, traffic light lists, MO news updates and more.

All the Rotherham MO documents from yourhealthrotherham.co.uk have been transferred over and can be searched separately or filtered to include other places across South Yorkshire and IMOC. Although the Rotherham Traffic Lights will remain, for items not yet harmonised across SY via IMOC.

There are user guides and video demos available on the website main page, or you can ask a member of your MO support for more information.

SystemOne - Irregular repeats

Warning – when ticking the “irregularly issued template” option for repeat prescriptions on systm1, this turns off the “issue duration” for the repeat template, allowing the patient to order early, even daily.

Therefore, prescribers should take care using the “irregularly issued template” function to ensure that the practice has a robust process in place that the duration between issues is double checked. This could include ensuring the “Use maximum issues” option is used at a low number (i.e. 2 or 3).

This is especially important for items such as SABAs, painkillers, pen needles etc. where a practice may have used a longer duration to ensure the patient isn't routinely collecting with their monthly medication.

SystemOne - OptimiseRx doses

Warning – when an OptimiseRx pop-up message suggests a change of brand/generic of a medication, it no longer keeps the original dose instructions for the patient but goes to the default dose for the product.

The prescriber will need to ensure that they know the dose instructions and quantity required before clicking to accept the alternative so they can ensure the patient continues with the correct dosage.





This issue has been raised with the TPP Help Desk with a development request for this to be corrected.

Adrenaline Auto Injection (AAI) Chart

There has recently been a safety update on Auto Adrenaline Injectors and the need for adjusting the dose according to patient's weight. We have produced guide for practices to follow and help aid Clinicians further. Below is the chart that is included in our guide.

The guide is on the new SY wide MO website: [Rotherham Factsheet Auto Adrenaline Injector Guide.docx](#)

PRESCRIBE BY BRAND ONLY
DOSE MUST BE CHECKED/ADJUSTED BY ACTUAL WEIGHT BEFORE EACH PRESCRIPTION

Product Name	Dose by weight in kilograms (kg)	Patient Information	Educational Material from Manufacture
EpiPen® Jr. 0.15 mg adrenaline (epinephrine) auto-injector 	Child between 7.5kg – 25kg 0.15mg dosage (Green Label) Adrenaline/epinephrine Drugs BNF NICE	EpiPen Junior 0.15mg PIL	EpiPen: For Patients EpiPen® Jr
EpiPen® 0.3 mg and adrenaline (epinephrine) auto-injector 	Adult and children over 25kg 0.3mg dosage (Yellow Label) Adrenaline/epinephrine Drugs BNF NICE	EpiPen Senior 0.3mg PIL	EpiPen: For Patients EpiPen®
Jext® 150 micrograms solution for injection in pre-filled pen 	Children between 15kg and 30kg . (Yellow label) Adrenaline/epinephrine Drugs BNF NICE	Jext Pen 150mcg/300mcg PIL	Home - Patients Jext
Jext® 300 micrograms solution for injection in pre-filled pen 	Adults and Children over 30kg (Red label) Adrenaline/epinephrine Drugs BNF NICE	Jext Pen 150mcg/300mcg PIL	Home - Patients Jext

Training Pens available: [EpiPen® - EpiPen® Training Pen](#) | [EpiPen®](#) [Jext® - Jext® - Training Pen](#)